Cytokinetics Inc [CYTK] stock is trading at $32.66, up 6.21%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYTK shares have gain 6.70% over the last week, with a monthly amount drifted -13.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on April 24, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $55. Previously, Citigroup started tracking the stock with Buy rating on February 07, 2025, and set its price target to $86. On January 22, 2025, Stifel initiated with a Buy rating and assigned a price target of $80 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $80 on November 08, 2024. Goldman downgraded its rating to a Neutral and reduced its price target to $60 on August 13, 2024. UBS downgraded its rating to Neutral for this stock on January 24, 2024, and upped its price target to $92. In a note dated January 05, 2024, Morgan Stanley downgraded an Equal-Weight rating on this stock and boosted its target price from $60 to $90.
Cytokinetics Inc [CYTK] stock has fluctuated between $29.31 and $61.40 over the past year. Currently, Wall Street analysts expect the stock to reach $61 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $32.66 at the most recent close of the market. An investor can expect a potential return of 86.77% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Cytokinetics Inc [NASDAQ:CYTK] reported sales of 19.22M for the trailing twelve months, which represents a growth of 89.10%. Gross Profit Margin for this corporation currently stands at -13.6% with Operating Profit Margin at -29.43%, Pretax Profit Margin comes in at -32.01%, and Net Profit Margin reading is -32.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 8.01 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Cytokinetics Inc’s Current Ratio is 5.99. Further, the Quick Ratio stands at 5.99, while the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 202.94.
Transactions by insiders
Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on May 20 ’25 when 2000.0 shares were sold. President & CEO, Blum Robert I completed a deal on May 16 ’25 to sell 5000.0 shares. Meanwhile, Director Bhanji Muna sold 1454.0 shares on May 15 ’25.
